Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

e-STORAGE Launches FlexBank 1.0, an 8.36 MWh Energy Storage Modular Battery, at RE+ 2025 in Las Vegas

(NASDAQ:CSIQ) KITCHENER, ON, Sept. 4, 2025 /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that e-STORAGE, which is part of the Company's majo...

What are the potential market adoption risks and timeline for commercial sales, and how might they influence the stock's valuation? How does the 8.36 MWh modular battery compare to competing storage solutions in terms of cost, performance, and deployment time? How will the launch of FlexBank 1.0 affect Canadian Solar's revenue guidance and earnings outlook?
Symbol: CSIQ
Product launch
9 days ago
Read more prnewswire

Brady Corporation Reports Record Adjusted EPS in its Fiscal 2025 Fourth Quarter and Announces its Fiscal 2026 EPS Guidance

(NYSE:BRC) MILWAUKEE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Brady Corporation (NYSE: BRC) (“Brady” or “Company”), a world leader in identification solutions, today reported its financial results for...

How does Brady's FY2026 EPS guidance stack up against its main competitors in the identification solutions space, and what does that imply for its market share and competitive positioning? What are the key drivers behind the EPS beat (e.g., pricing power, cost reductions, product mix) and are those drivers sustainable in upcoming quarters? How does the record adjusted EPS and FY2026 EPS guidance compare to consensus analyst estimates and what impact might that have on the stock's valuation?
Symbol: BRC
Earnings
9 days ago
Read more globenewswire

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYNDÂź (mitapivat) in Thalassemia

(NASDAQ:AGIO) Agios announced that the U.S. FDA has extended the PDUFA goal date for the sNDA of PYRUKYND for adults with thalassemia by three months to December 7, 2025

Will the extended timeline impact the company's cash burn rate and potential need for additional financing? What are the implications of the delay for AGIO's competitive positioning versus other thalassemia therapies in development? How will the three‑month PDUFA extension affect AGIO's revenue forecasts and runway for PYRUKYND?
Symbol: AGIO
Regulatory
9 days ago
Read more globenewswire

Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

(NASDAQ:SKYE) SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for...

Symbol: SKYE
Clinical trials
9 days ago
Read more globenewswire

G-III Apparel Group, Ltd. Reports Second Quarter Fiscal 2026 Results; Provides Updated Fiscal 2026 Outlook

(NASDAQ:GIII) NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- G-III Apparel Group, Ltd. (NasdaqGS: GIII) (“G-III” or the “Company”) today reported results for the second quarter of fiscal 2026, ende...

What are the potential implications of the updated outlook on the stock’s valuation and can we expect any strategic actions (e.g., cost‑cutting, brand portfolio shifts, or cap‑ex adjustments) moving forward? How does G‑III's second‑quarter performance compare to its peers in the apparel and wholesale sector regarding revenue growth, margin expansion, and inventory management? What are the key drivers behind any revisions to the Fiscal 2026 outlook, and how will they affect earnings forecasts?
Symbol: GIII
Earnings
9 days ago
Read more globenewswire